BEGIN:VCALENDAR
VERSION:2.0
PRODID:-// - ECPv6.6.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.biomed.cas.cz
X-WR-CALDESC:Akce na 
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Prague
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Prague:20250226T150000
DTEND;TZID=Europe/Prague:20250226T160000
DTSTAMP:20260421T183936
CREATED:20250218T115219Z
LAST-MODIFIED:20250218T115219Z
UID:2312-1740582000-1740585600@www.biomed.cas.cz
SUMMARY:Seminář Iris Durić
DESCRIPTION:“Transmembrane adaptor protein WBP1L: searching for its binding partners to understand its role in hematopoiesis” \nTransmembrane adaptor protein WBP1L\, also known as Outcome Predictor of Acute Leukemia 1 (OPAL1) was identified nearly 20 years ago as a positive prognostic marker in childhood acute lymphoblastic leukemia. More recently\, elevated WBP1L expression has also been linked to positive outcomes in ovarian cancer. Despite these clinical associations\, the physiological function of WBP1L has long remained unclear. Recently we demonstrated its involvement in the regulation of hematopoiesis\, hematopoietic stem cell functionality and hematopoietic stem cell performance during transplantation. As an adaptor protein\, WBP1L’s activity depends on its interacting partners. This presentation will describe our efforts to identify these proteins and understand their contributions to WBP1L function\, focusing on two novel interactions: one with the receptor for interferon gamma and the other with the SCFβ-TRCP1 ubiquitin ligase complex.
URL:https://www.biomed.cas.cz/event/seminar-iris-duric/
LOCATION:Posluchárna Milana Haška / Milan Hašek Auditorium
ORGANIZER;CN="%C3%9AMG":MAILTO:leona.krausova@img.cas.cz
END:VEVENT
END:VCALENDAR